Taking two TRAILS

Richard M Ransohoff; Bruce D Trapp

doi:10.1016/j.neuron.2005.04.028

Taking two TRAILS

Neuron. 2005 May 5;46(3):355-6. doi: 10.1016/j.neuron.2005.04.028.

Authors

Richard M Ransohoff¹, Bruce D Trapp

Affiliation

¹ Department of Neurosciences, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. [email protected]

PMID: 15882629
DOI: 10.1016/j.neuron.2005.04.028

Abstract

The TNF-related apoptosis-inducing ligand (TRAIL) has well-described anti-inflammatory effects in models of autoimmune disease, including experimental autoimmune encephalomyelitis (EAE). In this issue of Neuron, Aktas, Smorodchenko, and colleagues present evidence that TRAIL exerts anti-inflammatory effects, but also induces neuronal apoptosis, in EAE. This report poses the therapeutic challenge of facilitating TRAIL expression in the periphery while inhibiting TRAIL in the CNS.

Publication types

Comment
Review

MeSH terms

Animals
Apoptosis Regulatory Proteins
Encephalomyelitis, Autoimmune, Experimental / immunology
Encephalomyelitis, Autoimmune, Experimental / metabolism*
Humans
Membrane Glycoproteins / immunology
Membrane Glycoproteins / metabolism*
Neurons / metabolism
Neurons / pathology
TNF-Related Apoptosis-Inducing Ligand
Tumor Necrosis Factor-alpha / immunology
Tumor Necrosis Factor-alpha / metabolism*

Substances

Apoptosis Regulatory Proteins
Membrane Glycoproteins
TNF-Related Apoptosis-Inducing Ligand
TNFSF10 protein, human
Tumor Necrosis Factor-alpha